nach oben

European Radiology

Erschienen in:

13.05.2023 | Imaging Informatics and Artificial Intelligence

Role of MRI radiomics for the prediction of MYCN amplification in neuroblastomas

verfasst von: Adarsh Ghosh, Ensar Yekeler, Sara Reis Teixeira, Deepa Dalal, Lisa States

Erschienen in: European Radiology | Ausgabe 10/2023

Einloggen, um Zugang zu erhalten

Abstract

Objectives

We evaluate MR radiomics and develop machine learning–based classifiers to predict MYCN amplification in neuroblastomas.

Methods

A total of 120 patients with neuroblastomas and baseline MR imaging examination available were identified of whom 74 (mean age ± standard deviation [SD] of 6 years and 2 months ± 4 years and 9 months; 43 females and 31 males, 14 MYCN amplified) underwent imaging at our institution. This was therefore used to develop radiomics models. The model was tested in a cohort of children with the same diagnosis but imaged elsewhere (n = 46, mean age ± SD: 5 years 11 months ± 3 years 9 months, 26 females and 14 MYCN amplified). Whole tumour volumes of interest were adopted to extract first-order histogram and second-order radiomics features. Interclass correlation coefficient and maximum relevance and minimum redundancy algorithm were applied for feature selection. Logistic regression, support vector machine, and random forest were employed as the classifiers. Receiver operating characteristic (ROC) analysis was performed to evaluate the diagnostic accuracy of the classifiers on the external test set.

Results

The logistic regression model and the random forest both showed an AUC of 0.75. The support vector machine classifier obtained an AUC of 0.78 on the test set with a sensitivity of 64% and a specificity of 72%.

Conclusion

The study provides preliminary retrospective evidence demonstrating the feasibility of MRI radiomics in predicting MYCN amplification in neuroblastomas. Future studies are needed to explore the correlation between other imaging features and genetic markers and to develop multiclass predictive models.

Key Points

• MYCN amplification in neuroblastomas is an important determinant of disease prognosis.

• Radiomics analysis of pre-treatment MR examinations can be used to predict MYCN amplification in neuroblastomas.

• Radiomics machine learning models showed good generalisability to external test set, demonstrating reproducibility of the computational models.

Nur mit Berechtigung zugänglich

Li J, Thompson TD, Miller JW et al (2008) Cancer incidence among children and adolescents in the United States, 2001–2003. Pediatrics 121:e1470–e1477. https://doi.org/10.1542/peds.2007-2964CrossRefPubMed

Nakagawara A, Li Y, Izumi H et al (2018) Neuroblastoma. Jpn J Clin Oncol 48:214–241. https://doi.org/10.1093/jjco/hyx176CrossRefPubMed

Brodeur GM (2018) Spontaneous regression of neuroblastoma. Cell Tissue Res 372:277–286. https://doi.org/10.1007/s00441-017-2761-2CrossRefPubMedPubMedCentral

London WB, Castleberry RP, Matthay KK et al (2005) Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group. J Clin Oncol 23:6459–6465. https://doi.org/10.1200/JCO.2005.05.571CrossRefPubMed

Cohn SL, Pearson ADJ, London WB et al (2009) The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 27:289–297. https://doi.org/10.1200/JCO.2008.16.6785CrossRefPubMedPubMedCentral

Monclair T, Brodeur GM, Ambros PF et al (2009) The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 27:298–303. https://doi.org/10.1200/JCO.2008.16.6876CrossRefPubMedPubMedCentral

Ruiz-Pérez MV, Henley AB, Arsenian-Henriksson M (2017) The MYCN protein in health and disease. Genes 8(4):113. https://doi.org/10.3390/genes8040113CrossRefPubMedPubMedCentral

Tan E, Merchant K, Kn BP et al (2022) CT-based morphologic and radiomics features for the classification of MYCN gene amplification status in pediatric neuroblastoma. Childs Nerv Syst 38:1487–1495. https://doi.org/10.1007/s00381-022-05534-3CrossRefPubMed

Chen X, Wang H, Huang K et al (2021) CT-based radiomics signature with machine learning predicts MYCN amplification in pediatric abdominal neuroblastoma. Front Oncol 11:687884. https://doi.org/10.3389/fonc.2021.687884

10.

Wu H, Wu C, Zheng H et al (2021) Radiogenomics of neuroblastoma in pediatric patients: CT-based radiomics signature in predicting MYCN amplification. Eur Radiol 31:3080–3089. https://doi.org/10.1007/s00330-020-07246-1CrossRefPubMed

11.

Di Giannatale A, Di Paolo PL, Curione D et al (2021) Radiogenomics prediction for MYCN amplification in neuroblastoma: a hypothesis generating study. Pediatr Blood Cancer 68:e29110. https://doi.org/10.1002/pbc.29110

12.

Ambros PF, Ambros IM, Brodeur GM et al (2009) International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 100:1471–1482. https://doi.org/10.1038/sj.bjc.6605014CrossRefPubMedPubMedCentral

13.

Theissen J, Boensch M, Spitz R et al (2009) Heterogeneity of the MYCN oncogene in neuroblastoma. Clin Cancer Res 15:2085–2090. https://doi.org/10.1158/1078-0432.CCR-08-1648CrossRefPubMed

14.

Qian L, Yang S, Zhang S et al (2022) Prediction of MYCN amplification, 1p and 11q aberrations in pediatric neuroblastoma via pre-therapy 18F-FDG PET/CT radiomics. Front Med (Lausanne) 9:840777. https://doi.org/10.3389/fmed.2022.840777

15.

Feng L, Qian L, Yang S et al (2022) Prediction for mitosis-karyorrhexis index status of pediatric neuroblastoma via machine learning based 18F-FDG PET/CT radiomics. Diagnostics 12(2):262. https://doi.org/10.3390/diagnostics12020262CrossRefPubMedPubMedCentral

16.

Feng L, Qian L, Yang S et al (2022) Clinical parameters combined with radiomics features of PET/CT can predict recurrence in patients with high-risk pediatric neuroblastoma. BMC Med Imaging 22:102. https://doi.org/10.1186/s12880-022-00828-zCrossRefPubMedPubMedCentral

17.

Liu G, Poon M, Zapala MA et al (2022) Incorporating radiomics into machine learning models to predict outcomes of neuroblastoma. J Digit Imaging 35:605–612. https://doi.org/10.1007/s10278-022-00607-wCrossRefPubMedPubMedCentral

18.

Sun K, Zhu H, Chai W, Yan F (2022) TP53 mutation estimation based on MRI radiomics analysis for breast cancer. J Magn Reson Imaging. https://doi.org/10.1002/jmri.28323CrossRefPubMed

19.

Liu Y-F, Shu X, Qiao X-F et al (2022) Radiomics-based machine learning models for predicting P504s/P63 immunohistochemical expression: a noninvasive diagnostic tool for prostate cancer. Front Oncol 12:911426. https://doi.org/10.3389/fonc.2022.911426

20.

Meißner A-K, Gutsche R, Galldiks N et al (2021) Radiomics for the non-invasive prediction of the BRAF mutation status in patients with melanoma brain metastases. Neuro Oncol. https://doi.org/10.1093/neuonc/noab294CrossRefPubMedCentral

21.

Lee J, Steinmann A, Ding Y et al (2021) Radiomics feature robustness as measured using an MRI phantom. Sci Rep 11:3973. https://doi.org/10.1038/s41598-021-83593-3CrossRefPubMedPubMedCentral

22.

Bernatz S, Zhdanovich Y, Ackermann J et al (2021) Impact of rescanning and repositioning on radiomic features employing a multi-object phantom in magnetic resonance imaging. Sci Rep 11:14248. https://doi.org/10.1038/s41598-021-93756-xCrossRefPubMedPubMedCentral

23.

Saltybaeva N, Tanadini-Lang S, Vuong D et al (2022) Robustness of radiomic features in magnetic resonance imaging for patients with glioblastoma: multi-center study. Phys Imaging Radiat Oncol 22:131–136. https://doi.org/10.1016/j.phro.2022.05.006CrossRefPubMedPubMedCentral

24.

Crombé A, Kind M, Fadli D et al (2020) Intensity harmonization techniques influence radiomics features and radiomics-based predictions in sarcoma patients. Sci Rep 10:15496. https://doi.org/10.1038/s41598-020-72535-0CrossRefPubMedPubMedCentral

25.

Nyúl LG, Udupa JK, Zhang X (2000) New variants of a method of MRI scale standardization. IEEE Trans Med Imaging 19:143–150. https://doi.org/10.1109/42.836373CrossRefPubMed

26.

Davatzikos C, Rathore S, Bakas S et al (2018) Cancer imaging phenomics toolkit: quantitative imaging analytics for precision diagnostics and predictive modeling of clinical outcome. J Med Imaging (Bellingham) 5:011018. https://doi.org/10.1117/1.JMI.5.1.011018

27.

Pati S, Singh A, Rathore S et al (2020) The cancer imaging phenomics toolkit (captk): technical overview. Brainlesion 11993:380–394. https://doi.org/10.1007/978-3-030-46643-5_38CrossRefPubMedPubMedCentral

28.

Diciotti S, Ciulli S, Mascalchi M et al (2013) The “peeking” effect in supervised feature selection on diffusion tensor imaging data. AJNR Am J Neuroradiol 34:E107–E107. https://doi.org/10.3174/ajnr.A3685CrossRefPubMedPubMedCentral

29.

An Introduction to ‘glmnet’ • glmnet. https://glmnet.stanford.edu/articles/glmnet.html. Accessed 6 Dec 2022

30.

Ghosh A, Yekeler E, Dalal D et al (2022) Whole-tumour apparent diffusion coefficient (ADC) histogram analysis to identify MYCN-amplification in neuroblastomas: preliminary results. Eur Radiol 32:8453–8462. https://doi.org/10.1007/s00330-022-08750-2CrossRefPubMed

31.

Huang M, Weiss WA (2013) Neuroblastoma and MYCN. Cold Spring Harb Perspect Med 3:a014415. https://doi.org/10.1101/cshperspect.a014415

32.

Lee JW, Son MH, Cho HW et al (2018) Clinical significance of MYCN amplification in patients with high-risk neuroblastoma. Pediatr Blood Cancer 65:e27257. https://doi.org/10.1002/pbc.27257

33.

Brisse HJ, Blanc T, Schleiermacher G et al (2017) Radiogenomics of neuroblastomas: relationships between imaging phenotypes, tumor genomic profile and survival. PLoS ONE 12:e0185190. https://doi.org/10.1371/journal.pone.0185190

34.

Shur JD, Doran SJ, Kumar S et al (2021) Radiomics in oncology: a practical guide. Radiographics 41:1717–1732. https://doi.org/10.1148/rg.2021210037CrossRefPubMed

35.

Rožanec J, Poštuvan T, Fortuna B, Mladenić D (2021) Tackling class imbalance in radiomics: the COVID-19 use case. In Ljubljana ’21: Slovenian KDD Conference on Data Mining and Data Warehouses, October, 2021, Ljubljana, Slovenia. ACM, New York, NY, USA, p 4. https://ailab.ijs.si/dunja/SiKDD2021/Papers/Ro%C5%BEanecetal.pdf

36.

Vabalas A, Gowen E, Poliakoff E, Casson AJ (2019) Machine learning algorithm validation with a limited sample size. PLoS ONE 14:e0224365. https://doi.org/10.1371/journal.pone.0224365

Titel: Role of MRI radiomics for the prediction of MYCN amplification in neuroblastomas
verfasst von: Adarsh Ghosh
Ensar Yekeler
Sara Reis Teixeira
Deepa Dalal
Lisa States
Publikationsdatum: 13.05.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 10/2023
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-023-09628-7

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Role of MRI radiomics for the prediction of MYCN amplification in neuroblastomas